<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.annals-general-psychiatry.com/feeds/mostaccessed/journal?quantity=&amp;format=rss&amp;version=">
        <title>Annals of General Psychiatry - Most accessed articles</title>
        <link>http://www.annals-general-psychiatry.com</link>
        <description>The most accessed research articles published by Annals of General Psychiatry</description>
        <dc:date>2012-05-06T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/11/1/10" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/11/1/13" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/5/1/16" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/4/1/17" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/11/1/12" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/7/1/4" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/7/1/9" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/10/1/2" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/11/1/9" />
                                <rdf:li rdf:resource="http://www.annals-general-psychiatry.com/content/11/1/11" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/11/1/10">
        <title>Treatment received, satisfaction with health care services, and psychiatric symptoms 3 months after hospitalization for self-poisoning</title>
        <description>Background:
Patients who self-poison have high repetition and high mortality rates. Therefore, appropriate follow-up is important. The aims of the present work were to study treatment received, satisfaction with health care services, and psychiatric symptoms after hospitalization for self-poisoning.
Methods:
A cohort of patients who self-poisoned (n = 867) over a period of 1 year received a questionnaire 3 months after discharge. The Beck Depression Inventory (BDI), Beck Hopelessness Scale (BHS), and Generalized Self-Efficacy Scale (GSE) were used. The participation rate was 28% (n = 242); mean age, 41 years; 66% females.
Results:
Although only 14% of patients were registered without follow-up referrals at discharge, 41% reported no such measures. Overall, satisfaction with treatment was fairly good, although 29% of patients waited more than 3 weeks for their first appointment. A total of 22% reported repeated self-poisoning and 17% cutting. The mean BDI and BHS scores were 23.3 and 10.1, respectively (both moderate to severe). The GSE score was 25.2. BDI score was 25.6 among patients with suicide attempts, 24.9 for appeals, and 20.1 for substance-use-related poisonings.
Conclusions:
Despite plans for follow-up, many patients reported that they did not receive any. The reported frequency of psychiatric symptoms and self-harm behavior indicate that a more active follow-up is needed.</description>
        <link>http://www.annals-general-psychiatry.com/content/11/1/10</link>
                <dc:creator>Tine Grimholt</dc:creator>
                <dc:creator>Mari Bjornaas</dc:creator>
                <dc:creator>Dag Jacobsen</dc:creator>
                <dc:creator>Gudrun Dieserud</dc:creator>
                <dc:creator>Oivind Ekeberg</dc:creator>
                <dc:source>Annals of General Psychiatry 2012, null:10</dc:source>
        <dc:date>2012-04-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-11-10</dc:identifier>
                                <prism:require>/content/figures/1744-859X-11-10-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2012-04-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/11/1/13">
        <title>Deep transcranial magnetic stimulation add-on for the treatment of auditory hallucinations: a double-blind study</title>
        <description>Background:
About 25% of schizophrenia patients with auditory hallucinations are refractory to pharmacotherapy and electroconvulsive therapy. We conducted a deep transcranial magnetic stimulation (TMS) pilot study in order to evaluate the potential clinical benefit of repeated left temporoparietal cortex stimulation in these patients. The results were encouraging, but a sham-controlled study was needed to rule out a placebo effect.
Methods:
A total of 18 schizophrenic patients with refractory auditory hallucinations were recruited, from Beer Yaakov MHC and other hospitals outpatient populations. Patients received 10 daily treatment sessions with low-frequency (1 Hz for 10 min) deep TMS applied over the left temporoparietal cortex, using the H1 coil at the intensity of 110% of the motor threshold. Procedure was either real or sham according to patient randomization. Patients were evaluated via the Auditory Hallucinations Rating Scale, Scale for the Assessment of Positive Symptoms-Negative Symptoms, Clinical Global Impressions, and Quality of Life Questionnaire.
Results:
In all, 10 patients completed the treatment (10 TMS sessions). Auditory hallucination scores of both groups improved; however, there was no statistical difference in any of the scales between the active and the sham treated groups.
Conclusions:
Low-frequency deep TMS to the left temporoparietal cortex using the protocol mentioned above has no statistically significant effect on auditory hallucinations or the other clinical scales measured in schizophrenic patients.Clinicaltrials.gov identifier: NCT00564096.</description>
        <link>http://www.annals-general-psychiatry.com/content/11/1/13</link>
                <dc:creator>Oded Rosenberg</dc:creator>
                <dc:creator>Roman Gersner</dc:creator>
                <dc:creator>Limor Dinur Klein</dc:creator>
                <dc:creator>Moshe Kotler</dc:creator>
                <dc:creator>Abraham Zangen</dc:creator>
                <dc:creator>Pinhas Dannon</dc:creator>
                <dc:source>Annals of General Psychiatry 2012, null:13</dc:source>
        <dc:date>2012-05-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-11-13</dc:identifier>
                                <prism:require>/content/figures/1744-859X-11-13-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>13</prism:startingPage>
        <prism:publicationDate>2012-05-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/5/1/16">
        <title>A cross-sectional analysis of video games and attention deficit hyperactivity disorder symptoms in adolescents</title>
        <description>Background:
Excessive use of the Internet has been associated with attention deficit hyperactivity disorder (ADHD), but the relationship between video games and ADHD symptoms in adolescents is unknown.MethodA survey of adolescents and parents (n = 72 adolescents, 72 parents) was performed assessing daily time spent on the Internet, television, console video games, and Internet video games, and their association with academic and social functioning. Subjects were high school students in the ninth and tenth grade. Students were administered a modified Young&apos;s Internet Addiction Scale (YIAS) and asked questions about exercise, grades, work, and school detentions. Parents were asked to complete the Conners&apos; Parent Rating Scale (CPRS) and answer questions regarding medical/psychiatric conditions in their child.
Results:
There was a significant association between time spent playing games for more than one hour a day and YIAS (p &lt; 0.001), overall grade point average (p &#8804; 0.019), and the &quot;Inattention&quot; and &quot;ADHD&quot; components of the CPRS (p &#8804; 0.001 and p &#8804; 0.020, respectively). No significant association was found between body mass index (BMI), exercise, number of detentions, or the &quot;Oppositional&quot; and &quot;Hyperactivity&quot; components of CPRS and video game use.
Conclusion:
Adolescents who play more than one hour of console or Internet video games may have more or more intense symptoms of ADHD or inattention than those who do not. Given the possible negative effects these conditions may have on scholastic performance, the added consequences of more time spent on video games may also place these individuals at increased risk for problems in school.</description>
        <link>http://www.annals-general-psychiatry.com/content/5/1/16</link>
                <dc:creator>Philip Chan</dc:creator>
                <dc:creator>Terry Rabinowitz</dc:creator>
                <dc:source>Annals of General Psychiatry 2006, null:16</dc:source>
        <dc:date>2006-10-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-5-16</dc:identifier>
                                <prism:require>/content/figures/1744-859X-5-16-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>16</prism:startingPage>
        <prism:publicationDate>2006-10-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/4/1/17">
        <title>No aggression in a 4-year-old boy with an androgen-producing tumour: Case Report</title>
        <description>Background:
The androgen testosterone plays a critical role in many aspects of sexual differentiation. Also, it is thought to induce aggressive behaviours or to play a role in social dominance.Case presentationIn this case report a 4-year-old boy is described whose testosterone and dehydroepiandrosterone sulphate (DHEA-S) levels were raised to pubertal levels due to a testosterone producing testis tumour. This provided the unique opportunity to examine the effects of elevated levels of androgens on levels of aggression or on social dominance before the onset of puberty.
Conclusion:
The present case report does not support the hypothesis of a causal relationship between testosterone and aggression or between testosterone and social dominance in young children.</description>
        <link>http://www.annals-general-psychiatry.com/content/4/1/17</link>
                <dc:creator>Wouter De la Marche</dc:creator>
                <dc:creator>Karin Prinsen</dc:creator>
                <dc:creator>Annemieke Boot</dc:creator>
                <dc:creator>Robert Ferdinand</dc:creator>
                <dc:source>Annals of General Psychiatry 2005, null:17</dc:source>
        <dc:date>2005-10-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-4-17</dc:identifier>
                                <prism:require>/content/figures/1744-859X-4-17-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>17</prism:startingPage>
        <prism:publicationDate>2005-10-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/11/1/12">
        <title>Treatment of refractory catatonic schizophrenia with low dose aripiprazole </title>
        <description>This case report concerns a 54-year-old woman with catatonic schizophrenia, characterized by treatment resistance to pharmacotherapy with olanzapine, risperidone and flunitrazepam, and electroconvulsive therapy (ECT). In this case, olanzapine and risperidone and flunitrazepam did not improve her catatonic and psychotic symptoms, and induced extrapyramidal symptoms. The effects of ECT did not continue even for a month. However, treatment with low-dose aripiprazole dramatically improved the patient&apos;s psychotic symptoms and extrapyramidal symptoms. The mechanisms underlying the effects of low-dose aripiprazole in this case remain unclear, but unlike other antipsychotics aripiprazole is a dopamine D2 partial agonist. In this regard, our results suggest that aripiprazole has numerous advantages, especially in cases of stuporous catatonia and a defective general status such as the present case.</description>
        <link>http://www.annals-general-psychiatry.com/content/11/1/12</link>
                <dc:creator>Tsuyoshi Sasaki</dc:creator>
                <dc:creator>Tasuku Hashimoto</dc:creator>
                <dc:creator>Tomihisa Niitsu</dc:creator>
                <dc:creator>Nobuhisa Kanahara</dc:creator>
                <dc:creator>Masaomi Iyo</dc:creator>
                <dc:source>Annals of General Psychiatry 2012, null:12</dc:source>
        <dc:date>2012-05-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-11-12</dc:identifier>
                                <prism:require>/content/figures/1744-859X-11-12-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>12</prism:startingPage>
        <prism:publicationDate>2012-05-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/7/1/4">
        <title>Hospital Anxiety and Depression Scale (HADS): validation in a Greek general hospital sample</title>
        <description>Background:
The Hospital Anxiety and Depression Scale (HADS) has been used in several languages to assess anxiety and depression in general hospital patients with good results.
Methods:
The HADS was administered to 521 participants (275 controls and 246 inpatients and outpatients of the Internal Medicine and Surgical Departments in &apos;Attikon&apos; General Hospital in Athens). The Beck Depression Inventory (BDI) and the State-Trait Anxiety Inventory (STAI) were used as &apos;gold standards&apos; for depression and anxiety respectively.
Results:
The HADS presented high internal consistency; Cronbach&apos;s &#945; cofficient was 0.884 (0.829 for anxiety and 0.840 for depression) and stability (test-retest intraclass correlation coefficient 0.944). Factor analysis showed a two-factor structure. The HADS showed high concurrent validity; the correlations of the scale and its subscales with the BDI and the STAI were high (0.722 &#8211; 0.749).
Conclusion:
The Greek version of HADS showed good psychometric properties and could serve as a useful tool for clinicians to assess anxiety and depression in general hospital patients.</description>
        <link>http://www.annals-general-psychiatry.com/content/7/1/4</link>
                <dc:creator>Ioannis Michopoulos</dc:creator>
                <dc:creator>Athanasios Douzenis</dc:creator>
                <dc:creator>Christina Kalkavoura</dc:creator>
                <dc:creator>Christos Christodoulou</dc:creator>
                <dc:creator>Panayiota Michalopoulou</dc:creator>
                <dc:creator>Georgia Kalemi</dc:creator>
                <dc:creator>Katerina Fineti</dc:creator>
                <dc:creator>Paulos Patapis</dc:creator>
                <dc:creator>Konstantinos Protopapas</dc:creator>
                <dc:creator>Lefteris Lykouras</dc:creator>
                <dc:source>Annals of General Psychiatry 2008, null:4</dc:source>
        <dc:date>2008-03-06T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-7-4</dc:identifier>
                                <prism:require>/content/figures/1744-859X-7-4-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2008-03-06T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/7/1/9">
        <title>Mourning and melancholia revisited: correspondences between principles of Freudian metapsychology and empirical findings in neuropsychiatry</title>
        <description>Freud began his career as a neurologist studying the anatomy and physiology of the nervous system, but it was his later work in psychology that would secure his place in history. This paper draws attention to consistencies between physiological processes identified by modern clinical research and psychological processes described by Freud, with a special emphasis on his famous paper on depression entitled &apos;Mourning and melancholia&apos;. Inspired by neuroimaging findings in depression and deep brain stimulation for treatment resistant depression, some preliminary physiological correlates are proposed for a number of key psychoanalytic processes. Specifically, activation of the subgenual cingulate is discussed in relation to repression and the default mode network is discussed in relation to the ego. If these correlates are found to be reliable, this may have implications for the manner in which psychoanalysis is viewed by the wider psychological and psychiatric communities.</description>
        <link>http://www.annals-general-psychiatry.com/content/7/1/9</link>
                <dc:creator>Robin Carhart-Harris</dc:creator>
                <dc:creator>Helen Mayberg</dc:creator>
                <dc:creator>Andrea Malizia</dc:creator>
                <dc:creator>David Nutt</dc:creator>
                <dc:source>Annals of General Psychiatry 2008, null:9</dc:source>
        <dc:date>2008-07-24T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-7-9</dc:identifier>
                                <prism:require>/content/figures/1744-859X-7-9-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2008-07-24T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/10/1/2">
        <title>Guidelines for rating Global Assessment of Functioning (GAF)</title>
        <description>Background:
Global Assessment of Functioning (GAF) is a scoring system for the severity of illness in psychiatry. It is used clinically in many countries, as well as in research, but studies have shown several problems with GAF, for example concerning its validity and reliability. Guidelines for rating are important. The present study aimed to identify the current status of guidelines for rating GAF, and relevant factors and gaps in knowledge for the development of improved guidelines.
Methods:
A thorough literature search was conducted.
Results:
Few studies of existing guidelines have been conducted; existing guidelines are short; and rating has a subjective element. Seven main categories were identified as being important in relation to further development of guidelines: (1) general points about guidelines for rating GAF; (2) introduction to guidelines, with ground rules; (3) starting scoring at the top, middle or bottom level of the scale; (4) scoring for different time periods and of different values (highest, lowest or average); (5) the finer grading of the scale; (6) different guidelines for different conditions; and (7) different languages and cultures. Little information is available about how rules for rating are understood by different raters: the final score may be affected by whether the rater starts at the top, middle or bottom of the scale; there is little data on which value/combination of GAF values to record; guidelines for scoring within 10-point intervals are limited; there is little empirical information concerning the suitability of existing guidelines for different conditions and patient characteristics; and little is known about the effects of translation into different languages or of different cultural understanding.
Conclusions:
Few studies have dealt specifically with guidelines for rating GAF. Current guidelines for rating GAF are not comprehensive, and relevant points for new guidelines are presented. Theoretical and empirical studies, and international expert panels would be valuable, as well as production of a manual with more information about scoring. Computerised assessment may well be the future.</description>
        <link>http://www.annals-general-psychiatry.com/content/10/1/2</link>
                <dc:creator>I. H. Monrad Aas</dc:creator>
                <dc:source>Annals of General Psychiatry 2011, null:2</dc:source>
        <dc:date>2011-01-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-10-2</dc:identifier>
                                <prism:require>/content/figures/1744-859X-10-2-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2011-01-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/11/1/9">
        <title>The role of cytokines and hot flashes in perimenopausal depression</title>
        <description>Background:
An imbalance in the production of proinflammatory and anti-inflammatory cytokines may play a role in the pathophysiology of perimenopausal depression. The aim of this study was to examine serum levels of the proinflammatory cytokines interleukin 6 (IL-6) and tumor necrosis factor &#945; (TNF&#945;), and the anti-inflammatory cytokine IL-10, in perimenopausal women suffering from depression. Furthermore, to assess whether serum cytokine levels are associated with the presence of hot flashes or the use of selective serotonin reuptake inhibitors (SSRIs). We also evaluated the possible association of hot flashes and perimenopausal depression.
Methods:
Serum samples from 65 perimenopausal women, 41 with depression and 24 without depression, were assessed for serum IL-6, TNF&#945; and IL-10 by conventional enzyme-linked immunosorbent assays. Depression was evaluated by the 17-item Hamilton Depression Rating Scale (HAM-D 17) and a psychiatric interview. The presence and severity of hot flashes were examined using the Menopause Rating Scale (MRS).
Results:
Serum levels cytokines did not differ between depressed women and normal controls. Serum levels of cytokines did not change significantly in depressed women with hot flashes or in depressed women treated with SSRIs. Hot flashes were strongly associated (P &lt; 0.0001) with perimenopausal depression.
Conclusion:
The study supports the hypothesis that perimenopausal depression is not characterized by increased proinflammatory cytokines and decreased anti-inflammatory cytokines. Women with perimenopausal depression suffer from more severe and more frequent hot flashes than women without perimenopausal depression.</description>
        <link>http://www.annals-general-psychiatry.com/content/11/1/9</link>
                <dc:creator>Sokratis Karaoulanis</dc:creator>
                <dc:creator>Alexandros Daponte</dc:creator>
                <dc:creator>Katerina Rizouli</dc:creator>
                <dc:creator>Andreas Rizoulis</dc:creator>
                <dc:creator>Georgios Lialios</dc:creator>
                <dc:creator>Catherine Theodoridou</dc:creator>
                <dc:creator>Christos Christakopoulos</dc:creator>
                <dc:creator>Nikiforos Angelopoulos</dc:creator>
                <dc:source>Annals of General Psychiatry 2012, null:9</dc:source>
        <dc:date>2012-04-10T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-11-9</dc:identifier>
                                <prism:require>/content/figures/1744-859X-11-9-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2012-04-10T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.annals-general-psychiatry.com/content/11/1/11">
        <title>Body composition in patients with schizophrenia: comparison with healthy controls</title>
        <description>Background:
Recently, a relationship between obesity and schizophrenia has been reported. Although fat mass and fat-free mass have been shown to be more predictive of health risk than body mass index, there are limited findings about body composition among patients suffering from schizophrenia. The aim of this study was to compare the body composition of schizophrenia patients with that of healthy subjects in Japan.
Methods:
We recruited patients (n = 204), aged 41.3 +/- 13.8 (mean +/- SD) years old with a Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) diagnosis of schizophrenia who were admitted to psychiatric hospital using a cross-sectional design. Subjects&apos; anthropometric measurements including weight, height, body mass index (BMI), and medications were also collected. Body fat, percentage (%) body fat, fat-free mass, muscle mass, and body water were measured using the bioelectrical impedance analysis (BIA) method. A comparative analysis was performed with schizophrenic subjects and 204 healthy control individuals.
Results:
In a multiple regression model with age, body mass index, and dose in chlorpromazine equivalents, schizophrenia was significantly linked with more body fat, higher percentage body fat, lower fat-free mass, lower muscle mass, and lower body water among males. In females, schizophrenia had a significant association with lower percentage body fat, higher fat-free mass, higher muscle mass, and higher body water.
Conclusions:
Our data demonstrate gender differences with regard to changes in body composition in association with schizophrenia. These results indicate that intervention programs designed to fight obesity among schizophrenic patients should be individualized according to gender.</description>
        <link>http://www.annals-general-psychiatry.com/content/11/1/11</link>
                <dc:creator>Norio Sugawara</dc:creator>
                <dc:creator>Norio Yasui-Furukori</dc:creator>
                <dc:creator>Shoko Tsuchimine</dc:creator>
                <dc:creator>Akira Fujii</dc:creator>
                <dc:creator>Yasushi Sato</dc:creator>
                <dc:creator>Manabu Saito</dc:creator>
                <dc:creator>Masashi Matsuzaka</dc:creator>
                <dc:creator>Ippei Takahashi</dc:creator>
                <dc:creator>Sunao Kaneko</dc:creator>
                <dc:source>Annals of General Psychiatry 2012, null:11</dc:source>
        <dc:date>2012-05-03T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1744-859X-11-11</dc:identifier>
                                <prism:require>/content/figures/1744-859X-11-11-toc.gif</prism:require>
                <prism:publicationName>Annals of General Psychiatry</prism:publicationName>
        <prism:issn>1744-859X</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2012-05-03T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>

